CY1108734T1 - Αναπτυξη αντισωματων ειδικων για hcv - Google Patents

Αναπτυξη αντισωματων ειδικων για hcv

Info

Publication number
CY1108734T1
CY1108734T1 CY20091100101T CY091100101T CY1108734T1 CY 1108734 T1 CY1108734 T1 CY 1108734T1 CY 20091100101 T CY20091100101 T CY 20091100101T CY 091100101 T CY091100101 T CY 091100101T CY 1108734 T1 CY1108734 T1 CY 1108734T1
Authority
CY
Cyprus
Prior art keywords
hcv
antibodies
development
specific antibodies
nob
Prior art date
Application number
CY20091100101T
Other languages
Greek (el)
English (en)
Inventor
Michael Houghton
Mark Selby
Sergio Abrignani
Jens Heile
Hagan Derek O´
Original Assignee
Novartis Vaccines And Diagnostics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines And Diagnostics, Inc. filed Critical Novartis Vaccines And Diagnostics, Inc.
Publication of CY1108734T1 publication Critical patent/CY1108734T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20091100101T 1999-12-01 2009-01-27 Αναπτυξη αντισωματων ειδικων για hcv CY1108734T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16823499P 1999-12-01 1999-12-01
US18505500P 2000-02-25 2000-02-25
EP00993586A EP1233782B1 (en) 1999-12-01 2000-12-01 Eliciting hcv-specific antibodies

Publications (1)

Publication Number Publication Date
CY1108734T1 true CY1108734T1 (el) 2014-04-09

Family

ID=26863907

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100101T CY1108734T1 (el) 1999-12-01 2009-01-27 Αναπτυξη αντισωματων ειδικων για hcv

Country Status (12)

Country Link
US (3) US7329408B2 (enExample)
EP (1) EP1233782B1 (enExample)
JP (1) JP2004500366A (enExample)
AT (1) ATE413190T1 (enExample)
AU (1) AU5442501A (enExample)
CA (1) CA2393251C (enExample)
CY (1) CY1108734T1 (enExample)
DE (1) DE60040755D1 (enExample)
DK (1) DK1233782T3 (enExample)
ES (1) ES2319727T3 (enExample)
PT (1) PT1233782E (enExample)
WO (1) WO2001047551A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1236801A (en) * 1999-10-27 2001-05-08 Chiron Corporation Activation of hcv-specific t cells
US7329408B2 (en) * 1999-12-01 2008-02-12 Novartis Vaccines And Diagnostics, Inc. Eliciting HCV-specific antibodies
AUPQ797700A0 (en) * 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
AU2002322358B2 (en) * 2001-06-29 2009-06-18 Novartis Vaccines And Diagnostics, Inc. HCV E1E2 vaccine compositions
CU23244A1 (es) * 2001-07-16 2007-10-17 Ct Ingenieria Genetica Biotech Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
CN1582337B (zh) 2001-10-11 2011-12-14 默沙东公司 丙型肝炎病毒疫苗
AU2003299994A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
US20050191358A1 (en) * 2003-01-14 2005-09-01 Derek O' Hagan Microparticles with adsorbed polynucleotide-containing species
WO2004071414A2 (en) * 2003-02-05 2004-08-26 Genzyme Corporation Therapeutic anti-hcv (al9) compounds
US20040203084A1 (en) * 2003-04-10 2004-10-14 Doug Levinson Profiling conformational variants, antibody compositions and methods of using the same
EP1622566A4 (en) * 2003-04-25 2008-06-25 Novartis Vaccines & Diagnostic COMPOSITIONS WITH CATIONIC MICROTEILS AND HCV E1E2 DNA AND METHOD OF APPLICATION THEREOF
CA2528007C (en) * 2003-06-02 2012-03-27 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
US20060088819A1 (en) * 2004-05-17 2006-04-27 Chiron Corporation Truncated hepatitis C virus NS5 domain and fusion proteins comprising same
AU2005294805B2 (en) 2004-05-28 2012-02-16 Oryxe A mixture for transdermal delivery of low and high molecular weight compounds
PT1801209E (pt) 2004-08-24 2011-05-26 Toray Industries Arn gen?mico do v?rus humano modificado da hepatite c com capacidade de replica??o aut?noma
DE602005027738D1 (de) * 2004-11-18 2011-06-09 Univ Hiroshima Nat Univ Corp Verfahren und kit zur expression von protein unter regulation der expression von einer durch genamplifikation gebildeten wiederholungssequenz und transformant
JP5405832B2 (ja) * 2006-01-04 2014-02-05 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｈｃｖ特異的なｔ細胞の活性化
JPWO2009014216A1 (ja) 2007-07-25 2010-10-07 国立感染症研究所長 Ｃ型肝炎ウイルス（ｈｃｖ）に対して感染阻害活性を有する抗体およびその用途
CN102596996B (zh) 2009-10-30 2014-06-18 东丽株式会社 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
CA2856565A1 (en) * 2010-11-26 2012-05-31 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd. Multimeric hepatitis virus (hcv) envelope 2 (e2) glycoprotein
JP6736464B2 (ja) 2013-08-29 2020-08-05 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 細胞透過性コンジュゲート及びその使用の方法
EP3349717A4 (en) 2015-09-17 2019-04-17 JRX Biotechnology, Inc. APPROACHES TO IMPROVE SKIN HYDROGENATION OR HUMIDIFICATION

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
EP0318216B2 (en) * 1987-11-18 2001-08-29 Chiron Corporation NANBV diagnostics
US5471330A (en) 1993-07-29 1995-11-28 Honeywell Inc. Polysilicon pixel electrode
EP0773957B1 (en) * 1994-07-29 2005-06-29 Chiron Corporation Secreted hepatitis C virus E1/E2 complex obtained from C-terminally truncated E1 and E2 polypeptides
WO1996004301A2 (en) 1994-07-29 1996-02-15 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
GB9416671D0 (en) 1994-08-17 1994-10-12 Biocine Spa Assay
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
EP0862419B2 (en) * 1995-11-09 2010-11-17 Microbiological Research Authority Microencapsulated dna for vaccination and gene therapy
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
WO1998050556A2 (en) 1997-05-06 1998-11-12 Chiron Corporation Intracellular production of hepatitis c e1 and e2 truncated polypeptides
EP0996730A1 (en) * 1997-07-18 2000-05-03 Connaught Laboratories Limited Nucleic acid vaccines encoding g protein of respiratory syncytial virus
CA2314934C (en) * 1997-12-16 2006-08-29 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
AU1236801A (en) 1999-10-27 2001-05-08 Chiron Corporation Activation of hcv-specific t cells
US7329408B2 (en) * 1999-12-01 2008-02-12 Novartis Vaccines And Diagnostics, Inc. Eliciting HCV-specific antibodies

Also Published As

Publication number Publication date
AU5442501A (en) 2001-07-09
ES2319727T3 (es) 2009-05-12
US20080095800A1 (en) 2008-04-24
PT1233782E (pt) 2009-02-13
US7329408B2 (en) 2008-02-12
EP1233782A2 (en) 2002-08-28
CA2393251A1 (en) 2001-07-05
EP1233782B1 (en) 2008-11-05
WO2001047551A3 (en) 2002-03-14
JP2004500366A (ja) 2004-01-08
ATE413190T1 (de) 2008-11-15
WO2001047551A2 (en) 2001-07-05
CA2393251C (en) 2012-01-31
US20110159039A1 (en) 2011-06-30
US20020002272A1 (en) 2002-01-03
DK1233782T3 (da) 2009-02-09
DE60040755D1 (de) 2008-12-18

Similar Documents

Publication Publication Date Title
CY1108734T1 (el) Αναπτυξη αντισωματων ειδικων για hcv
DK0693687T3 (da) Kombinationer af hepatitis C-virus (HCV)-antigener til anvendelse i immunoassays for anti-HCV-antistoffer
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
IL152825A0 (en) Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
HUP0303134A3 (en) Hiv peptides, antigens, vaccine compositions, immunoassay kits and method of detecting antibodies induced by hiv
WO2001098333A3 (en) Modification of hepatitis b core antigen
ATE17320T1 (de) Impfstoff, therapie gegen nicht-a nicht-b virale hepatitis und verfahren zur herstellung desselben.
DE69532062D1 (de) Immuntests von nicht-A, nicht-B Hepatitisvirus-verwandten Antigenen, monoklonale Antikörper und diese synthetisierende Hybridome
DE69531235D1 (de) Säugetier - Expressionssysteme für Hüllenprotingene des Hepatitit - C - Virus
EP1301208A4 (en) Vaccine
NO20051715L (no) HCV assay
DK1417233T3 (da) Humant rekombinant antistof mod det hepatitis C (HCV) ikke-strukturelle NS3-protein, nukleinsyre og anvendelser deraf
RU2008114385A (ru) ИНДУКТОР СЕКРЕТОРНЫХ АНТИТЕЛ IgA И IgG
EP0339668A3 (en) Hepatitis a virus antigen
DK0556320T3 (da) Monoklonale antistoffer mod Hepatitis C-virus og fremgangsmåde til anvendelse heraf
DK0599913T3 (da) Monoklonale antistoffer mod formodet hepatitis C-virus NS5-proteiner og anvendelsesmetoder af samme
DK0476059T3 (da) Fremgangsmåder til forøgelse af modificeringshastigheden for metastabile bindinger
LV10626A (lv) Peptidi
DE68918440D1 (de) Verfahren zur transformation von menschlichen b-lymphocyten.
WO2003014728A1 (fr) Medicaments contre l'hepatite c
DK375388A (da) Nanb hepatitisvirusmiddel, antigen og immunologisk reagens
DE69331796D1 (de) Kernantigenprotein des Hepatitis C-Virus, sowie diagnostisches Verfahren und Satz von Reagenzen
TH22297A (th) การวินิจฉัย nanbv และวัคซีน